Bloomington, Ind.
Catalent is initiating an expansion of its biologics manufacturing operations. The global biotechnology company will construct a 60,000-sf facility on its existing campus in Madison, Wis. The project is slated for completion by 2021 and represents an investment of $100 million over the next three years. Catalent will also invest $100 million to increase its manufacturing capacity in Bloomington, Ind. A 79,000-sf expansion will accommodate new fill/finish production lines, and an existing facility will undergo a $14 million renovation to provide five packaging suites and a quality control laboratory. Catalent is based in Somerset, N.J.
